Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 231 entries
Sorted by: Best Match Show Resources per page
Genetic characterization of fluoroquinolone-resistant Escherichia coli associated with bovine mastitis in India.

Veterinary world

Balakrishnan S, Antony PX, Mukhopadhyay HK, Pillai RM, Thanislass J, Padmanaban V, Srinivas MV.
PMID: 27536030
Vet World. 2016 Jul;9(7):705-9. doi: 10.14202/vetworld.2016.705-709. Epub 2016 Jul 11.

AIM: The present study was undertaken to characterize the mutation in gyrA (DNA gyrase) and parC (topoisomerase IV) genes responsible for fluoroquinolone resistance in Escherichia coli isolates associated with the bovine mastitis.MATERIALS AND METHODS: A total of 92 milk...

Cite
Balakrishnan S, Antony PX, Mukhopadhyay HK, et al. Genetic characterization of fluoroquinolone-resistant Escherichia coli associated with bovine mastitis in India. Vet World. 2016;9(7):705-9doi: 10.14202/vetworld.2016.705-709.
Balakrishnan, S., Antony, P. X., Mukhopadhyay, H. K., Pillai, R. M., Thanislass, J., Padmanaban, V., & Srinivas, M. V. (2016). Genetic characterization of fluoroquinolone-resistant Escherichia coli associated with bovine mastitis in India. Veterinary world, 9(7), 705-9. https://doi.org/10.14202/vetworld.2016.705-709
Balakrishnan, Sangeetha, et al. "Genetic characterization of fluoroquinolone-resistant Escherichia coli associated with bovine mastitis in India." Veterinary world vol. 9,7 (2016): 705-9. doi: https://doi.org/10.14202/vetworld.2016.705-709
Balakrishnan S, Antony PX, Mukhopadhyay HK, Pillai RM, Thanislass J, Padmanaban V, Srinivas MV. Genetic characterization of fluoroquinolone-resistant Escherichia coli associated with bovine mastitis in India. Vet World. 2016 Jul;9(7):705-9. doi: 10.14202/vetworld.2016.705-709. Epub 2016 Jul 11. PMID: 27536030; PMCID: PMC4983120.
Copy Download .nbib Format: NLM
Role of chaperones and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells after nutrient addition.

SpringerPlus

Gutiérrez-Estrada A, Ramírez-Santos J, Gómez-Eichelmann Mdel C.
PMID: 25485196
Springerplus. 2014 Nov 06;3:656. doi: 10.1186/2193-1801-3-656. eCollection 2014.

Escherichia coli stationary-phase (SP) cells contain relaxed DNA molecules and recover DNA supercoiling once nutrients become available. In these cells, the reactivation of DNA gyrase, which is a DNA topoisomerase type IIA enzyme, is responsible for the recovery of...

Cite
Gutiérrez-Estrada A, Ramírez-Santos J, Gómez-Eichelmann Mdel C. Role of chaperones and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells after nutrient addition. Springerplus. 2014;3:656doi: 10.1186/2193-1801-3-656.
Gutiérrez-Estrada, A., Ramírez-Santos, J., & Gómez-Eichelmann, M. d. e. l. . C. (2014). Role of chaperones and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells after nutrient addition. SpringerPlus, 3656. https://doi.org/10.1186/2193-1801-3-656
Gutiérrez-Estrada, Alejandra, et al. "Role of chaperones and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells after nutrient addition." SpringerPlus vol. 3 (2014): 656. doi: https://doi.org/10.1186/2193-1801-3-656
Gutiérrez-Estrada A, Ramírez-Santos J, Gómez-Eichelmann Mdel C. Role of chaperones and ATP synthase in DNA gyrase reactivation in Escherichia coli stationary-phase cells after nutrient addition. Springerplus. 2014 Nov 06;3:656. doi: 10.1186/2193-1801-3-656. eCollection 2014. PMID: 25485196; PMCID: PMC4230433.
Copy Download .nbib Format: NLM
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections.

Ophthalmology and therapy

Mah FS, Sanfilippo CM.
PMID: 27010720
Ophthalmol Ther. 2016 Jun;5(1):1-20. doi: 10.1007/s40123-016-0046-6. Epub 2016 Mar 24.

This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called...

Cite
Mah FS, Sanfilippo CM. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Ophthalmol Ther. 2016;5(1):1-20doi: 10.1007/s40123-016-0046-6.
Mah, F. S., & Sanfilippo, C. M. (2016). Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Ophthalmology and therapy, 5(1), 1-20. https://doi.org/10.1007/s40123-016-0046-6
Mah, Francis S, and Sanfilippo, Christine M. "Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections." Ophthalmology and therapy vol. 5,1 (2016): 1-20. doi: https://doi.org/10.1007/s40123-016-0046-6
Mah FS, Sanfilippo CM. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Ophthalmol Ther. 2016 Jun;5(1):1-20. doi: 10.1007/s40123-016-0046-6. Epub 2016 Mar 24. PMID: 27010720; PMCID: PMC4909673.
Copy Download .nbib Format: NLM
Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV.

ACS medicinal chemistry letters

O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL.
PMID: 26191374
ACS Med Chem Lett. 2015 Jun 22;6(7):822-6. doi: 10.1021/acsmedchemlett.5b00196. eCollection 2015 Jul 09.

Benzimidazole 1 is the lead compound resulting from an antibacterial program targeting dual inhibitors of bacterial DNA gyrase and topoisomerase IV. With the goal of improving key drug-like properties, namely, the solubility and the formulability of 1, an effort...

Cite
O'Dowd H, Shannon DE, Chandupatla KR, et al. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Med Chem Lett. 2015;6(7):822-6doi: 10.1021/acsmedchemlett.5b00196.
O'Dowd, H., Shannon, D. E., Chandupatla, K. R., Dixit, V., Engtrakul, J. J., Ye, Z., Jones, S. M., O'Brien, C. F., Nicolau, D. P., Tessier, P. R., Crandon, J. L., Song, B., Macikenas, D., Hanzelka, B. L., Le Tiran, A., Bennani, Y. L., Charifson, P. S., & Grillot, A. L. (2015). Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS medicinal chemistry letters, 6(7), 822-6. https://doi.org/10.1021/acsmedchemlett.5b00196
O'Dowd, Hardwin, et al. "Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV." ACS medicinal chemistry letters vol. 6,7 (2015): 822-6. doi: https://doi.org/10.1021/acsmedchemlett.5b00196
O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Med Chem Lett. 2015 Jun 22;6(7):822-6. doi: 10.1021/acsmedchemlett.5b00196. eCollection 2015 Jul 09. PMID: 26191374; PMCID: PMC4499827.
Copy Download .nbib Format: NLM
Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles.

MedChemComm

Ranjan N, Fulcrand G, King A, Brown J, Jiang X, Leng F, Arya DP.
PMID: 25083189
Medchemcomm. 2014 Jun 01;5(6):816-825. doi: 10.1039/C4MD00140K.

Hoechst dyes are well known DNA binders that non-selectively inhibit the function of mammalian topoisomerase I and II. Herein, we show that Hoechst 33258 based bisbenzimidazoles (DPA 151-154), containing a terminal alkyne, are effective and selective inhibitors of E....

Cite
Ranjan N, Fulcrand G, King A, et al. Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles. Medchemcomm. 2014;5(6):816-825doi: 10.1039/C4MD00140K.
Ranjan, N., Fulcrand, G., King, A., Brown, J., Jiang, X., Leng, F., & Arya, D. P. (2014). Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles. MedChemComm, 5(6), 816-825. https://doi.org/10.1039/C4MD00140K
Ranjan, Nihar, et al. "Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles." MedChemComm vol. 5,6 (2014): 816-825. doi: https://doi.org/10.1039/C4MD00140K
Ranjan N, Fulcrand G, King A, Brown J, Jiang X, Leng F, Arya DP. Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazoles. Medchemcomm. 2014 Jun 01;5(6):816-825. doi: 10.1039/C4MD00140K. PMID: 25083189; PMCID: PMC4112416.
Copy Download .nbib Format: NLM
A prospective, randomized, clinical study to compare the clinical safety, effectiveness, and cost of oral ofloxacin/clindamycin vs intravenous clindamycin/gentamicin for the treatment of postpartum endomyometritis.

Primary care update for Ob/Gyns

Pietrantoni M, Goss S, Gall SA.
PMID: 10838268
Prim Care Update Ob Gyns. 1998 Jul 01;5(4):146-147. doi: 10.1016/s1068-607x(98)00023-7.

Objective: The primary objective of this prospective, randomized, clinical study was to compare the safety, clinical and microbiologic efficacy, and cost of oral ofloxacin in combination with clindamycin vs intravenous (IV) clindamycin/gentamicin in the early empiric treatment for hospitalized...

Cite
Pietrantoni M, Goss S, Gall SA. A prospective, randomized, clinical study to compare the clinical safety, effectiveness, and cost of oral ofloxacin/clindamycin vs intravenous clindamycin/gentamicin for the treatment of postpartum endomyometritis. Prim Care Update Ob Gyns. 1998;5(4):146-147doi: 10.1016/s1068-607x(98)00023-7.
Pietrantoni, M., Goss, S., & Gall, S. A. (1998). A prospective, randomized, clinical study to compare the clinical safety, effectiveness, and cost of oral ofloxacin/clindamycin vs intravenous clindamycin/gentamicin for the treatment of postpartum endomyometritis. Primary care update for Ob/Gyns, 5(4), 146-147. https://doi.org/10.1016/s1068-607x(98)00023-7
Pietrantoni, et al. "A prospective, randomized, clinical study to compare the clinical safety, effectiveness, and cost of oral ofloxacin/clindamycin vs intravenous clindamycin/gentamicin for the treatment of postpartum endomyometritis." Primary care update for Ob/Gyns vol. 5,4 (1998): 146-147. doi: https://doi.org/10.1016/s1068-607x(98)00023-7
Pietrantoni M, Goss S, Gall SA. A prospective, randomized, clinical study to compare the clinical safety, effectiveness, and cost of oral ofloxacin/clindamycin vs intravenous clindamycin/gentamicin for the treatment of postpartum endomyometritis. Prim Care Update Ob Gyns. 1998 Jul 01;5(4):146-147. doi: 10.1016/s1068-607x(98)00023-7. PMID: 10838268.
Copy Download .nbib Format: NLM
Mechanisms of fluoroquinolone resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Hooper DC.
PMID: 11504468
Drug Resist Updat. 1999 Feb;2(1):38-55. doi: 10.1054/drup.1998.0068.

Mechanisms of bacterial resistance to fluoroquinolones fall into two principal categories, alterations in drug target enzymes and alterations that limit permeation of drug to the target, both resulting from chromosomal mutations. No specific resistance mechanisms of quinolone degradation or...

Cite
Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat. 1999;2(1):38-55doi: 10.1054/drup.1998.0068.
Hooper, D. C. (1999). Mechanisms of fluoroquinolone resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2(1), 38-55. https://doi.org/10.1054/drup.1998.0068
Hooper, David C.. "Mechanisms of fluoroquinolone resistance." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 2,1 (1999): 38-55. doi: https://doi.org/10.1054/drup.1998.0068
Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat. 1999 Feb;2(1):38-55. doi: 10.1054/drup.1998.0068. PMID: 11504468.
Copy Download .nbib Format: NLM
Fluoroquinolones: mechanisms of action and resistance.

International journal of antimicrobial agents

Bryskier A.
PMID: 18611533
Int J Antimicrob Agents. 1993;2(3):151-83. doi: 10.1016/0924-8579(93)90052-7.

The mechanism of action and the mechanism of resistance of the 4-quinolones are complex and poorly understood. The first barrier these molecules must cross is the bacterial outer membrane. In gram-negative species, 4-quinolones pass through either the porins or...

Cite
Bryskier A. Fluoroquinolones: mechanisms of action and resistance. Int J Antimicrob Agents. 1993;2(3):151-83doi: 10.1016/0924-8579(93)90052-7.
Bryskier, A. (1993). Fluoroquinolones: mechanisms of action and resistance. International journal of antimicrobial agents, 2(3), 151-83. https://doi.org/10.1016/0924-8579(93)90052-7
Bryskier, A. "Fluoroquinolones: mechanisms of action and resistance." International journal of antimicrobial agents vol. 2,3 (1993): 151-83. doi: https://doi.org/10.1016/0924-8579(93)90052-7
Bryskier A. Fluoroquinolones: mechanisms of action and resistance. Int J Antimicrob Agents. 1993;2(3):151-83. doi: 10.1016/0924-8579(93)90052-7. PMID: 18611533.
Copy Download .nbib Format: NLM
Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae.

Methods in molecular medicine

Vicente BJ, Luis MM.
PMID: 21374418
Methods Mol Med. 2001;48:189-97. doi: 10.1385/1-59259-077-2:189.

Antimicrobial treatment of Klebsiella pneumoniae infections can be complicated by the existence of multiply-antibiotic resistant (multiresistant) strains carrying plasmids coding for extended-spectrum β-lactamases (ESBLs), AmpC-type β-lactamases (ACTBLs), or aminoglycoside-modifying enzymes. This situation has become an increasingly serious problem worldwide...

Cite
Vicente BJ, Luis MM. Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae. Methods Mol Med. 2001;48:189-97doi: 10.1385/1-59259-077-2:189.
Vicente, B. J., & Luis, M. M. (2001). Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae. Methods in molecular medicine, 48189-97. https://doi.org/10.1385/1-59259-077-2:189
Vicente, B J, and Luis, M M. "Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae." Methods in molecular medicine vol. 48 (2001): 189-97. doi: https://doi.org/10.1385/1-59259-077-2:189
Vicente BJ, Luis MM. Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae. Methods Mol Med. 2001;48:189-97. doi: 10.1385/1-59259-077-2:189. PMID: 21374418.
Copy Download .nbib Format: NLM
Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach.

Genomics & informatics

Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R.
PMID: 30309202
Genomics Inform. 2018 Sep;16(3):44-51. doi: 10.5808/GI.2018.16.3.44. Epub 2018 Sep 30.

Fluoroquinolone (FQ) antibiotics are an important class of synthetic antibacterial agents. These are the most extensively used drugs for treating bacterial infections in the field of both human and veterinary medicine. Herein, the antibacterial and pharmacological properties of four...

Cite
Sood D, Kumar N, Singh A, et al. Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach. Genomics Inform. 2018;16(3):44-51doi: 10.5808/GI.2018.16.3.44.
Sood, D., Kumar, N., Singh, A., Sakharkar, M. K., Tomar, V., & Chandra, R. (2018). Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach. Genomics & informatics, 16(3), 44-51. https://doi.org/10.5808/GI.2018.16.3.44
Sood, Damini, et al. "Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach." Genomics & informatics vol. 16,3 (2018): 44-51. doi: https://doi.org/10.5808/GI.2018.16.3.44
Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R. Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach. Genomics Inform. 2018 Sep;16(3):44-51. doi: 10.5808/GI.2018.16.3.44. Epub 2018 Sep 30. PMID: 30309202; PMCID: PMC6187815.
Copy Download .nbib Format: NLM
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of .

Heliyon

Nakano R, Nakano A, Abe M, Nagano N, Asahara M, Furukawa T, Ono Y, Yano H, Okamoto R.
PMID: 30886932
Heliyon. 2019 Mar 02;5(3):e01291. doi: 10.1016/j.heliyon.2019.e01291. eCollection 2019 Mar.

Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (

Cite
Nakano R, Nakano A, Abe M, et al. Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of . Heliyon. 2019;5(3):e01291doi: 10.1016/j.heliyon.2019.e01291.
Nakano, R., Nakano, A., Abe, M., Nagano, N., Asahara, M., Furukawa, T., Ono, Y., Yano, H., & Okamoto, R. (2019). Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of . Heliyon, 5(3), e01291. https://doi.org/10.1016/j.heliyon.2019.e01291
Nakano, Ryuichi, et al. "Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of ." Heliyon vol. 5,3 (2019): e01291. doi: https://doi.org/10.1016/j.heliyon.2019.e01291
Nakano R, Nakano A, Abe M, Nagano N, Asahara M, Furukawa T, Ono Y, Yano H, Okamoto R. Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of . Heliyon. 2019 Mar 02;5(3):e01291. doi: 10.1016/j.heliyon.2019.e01291. eCollection 2019 Mar. PMID: 30886932; PMCID: PMC6403068.
Copy Download .nbib Format: NLM
Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant .

Infection and drug resistance

Król-Turmińska K, Olender A.
PMID: 30122961
Infect Drug Resist. 2018 Aug 06;11:1047-1053. doi: 10.2147/IDR.S162006. eCollection 2018.

PURPOSE: The purpose of this study was to investigate the molecular mechanisms of fluoroquinolone resistance in MATERIALS AND METHODS: A total of 150 non-duplicate clinical strains of RESULTS: It was observed that 16.7% of the studied isolates were drug...

Cite
Król-Turmińska K, Olender A. Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant . Infect Drug Resist. 2018;11:1047-1053doi: 10.2147/IDR.S162006.
Król-Turmińska, K., & Olender, A. (2018). Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant . Infection and drug resistance, 111047-1053. https://doi.org/10.2147/IDR.S162006
Król-Turmińska, Katarzyna, and Olender, Alina. "Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant ." Infection and drug resistance vol. 11 (2018): 1047-1053. doi: https://doi.org/10.2147/IDR.S162006
Król-Turmińska K, Olender A. Alternations in DNA gyrase genes in low-level fluoroquinolone-resistant . Infect Drug Resist. 2018 Aug 06;11:1047-1053. doi: 10.2147/IDR.S162006. eCollection 2018. PMID: 30122961; PMCID: PMC6084068.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 231 entries